Contineum Therapeutics, Inc.
For the period ended May 14, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 14, 2025 · Filed May 14, 2025
Use the contents to explore the available documents and sections.
CTNM$9.52+8.1%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in thousands, except share and par value data)
(in thousands, except share and par value data)
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $22,470 | $21,943 |
| Marketable securities | 168,240 | 182,817 |
| Prepaid expenses and other current assets | 1,424 | 1,628 |
| Total current assets | 192,134 | 206,388 |
| Property and equipment, net | 891 | 989 |
| Other long-term assets | 4 | 3 |
| Operating lease right-of-use assets | 5,235 | 5,467 |
| Total assets | $198,264 | $212,847 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,645 | $1,811 |
| Accrued expenses | 3,849 | 6,711 |
| Current portion of operating lease liabilities | 1,455 | 1,452 |
| Total current liabilities | 8,949 | 9,974 |
| Operating lease liabilities, net of current portion | 4,547 | 4,807 |
| Total liabilities | 13,496 | 14,781 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Class A common stock, $0.001 par value; authorized shares—200,000,000 at March 31, 2025 and December 31, 2024; issued and outstanding shares—19,142,377 and 19,125,377 at March 31, 2025 and December 31, 2024, respectively. | 19 | 19 |
| Class B common stock, $0.001 par value; authorized shares—20,000,000 at March 31, 2025 and December 31, 2024; issued and outstanding shares—6,729,172 at March 31, 2025 and December 31, 2024. | 7 | 7 |
| Preferred stock, $0.001 par value; authorized shares—10,000,000 at March 31, 2025 and December 31, 2024; no shares issued or outstanding at March 31, 2025 and December 31, 2024. | — | — |
| Additional paid-in-capital | 317,964 | 315,371 |
| Accumulated deficit | (133,392) | (117,402) |
| Accumulated other comprehensive income | 170 | 71 |
| Total stockholders’ equity | 184,768 | 198,066 |
| Total liabilities and stockholders’ equity | $198,264 | $212,847 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.